Management of Severe Asthma Exacerbations

Introduction to Management Strategies

Ketamine has limited evidence for routine use in asthma exacerbations but may be considered as a temporizing measure in severe, refractory cases to avoid intubation, while fentanyl has no established role and may worsen respiratory depression, and NIPPV can provide short-term respiratory support in alert patients with adequate respiratory effort 1

The American Heart Association guidelines note that ketamine has sedative and analgesic properties that may be useful if intubation is planned, but do not recommend it as routine therapy 3, 1
Ketamine stimulates copious bronchial secretions, which can worsen airway obstruction—this must be managed with anticholinergics like glycopyrrolate or atropine 1, 4

Opioids like fentanyl are contraindicated in acute asthma management unless the patient is already intubated and mechanically ventilated, where they serve only as sedation/analgesia adjuncts 5, 6

NIPPV may offer short-term support for patients with acute respiratory failure and may delay or eliminate the need for endotracheal intubation 1, 2
The American Heart Association notes NIPPV "may" be beneficial but does not provide definitive guidance 1, 7
If frequent or severe airway obstruction or hypoxemia occurs during NIPPV, it should be discontinued and intubation considered 7

Continuous nebulized albuterol with ipratropium bromide should be administered as part of maximizing standard therapy 1, 2
Systemic corticosteroids should be given, with no advantage to the IV route over the PO route 8
IV magnesium sulfate 2g over 20 minutes is recommended as part of standard therapy 2
Indications for immediate intubation include apnea, coma, persistent/increasing hypercapnia, exhaustion, severe distress, depressed mental status 1, 2
If intubation appears imminent, ketamine may be considered as a temporizing measure, with administration of anticholinergics to counteract ketamine-induced secretions 4
Post-intubation, fentanyl becomes appropriate as first-line sedation/analgesia, and aggressive bronchodilator therapy should be continued 5, 6, 1